Difference between revisions of "Talk:Papillary thyroid carcinoma"
Jump to navigation
Jump to search
(→IHC: new section) |
|||
Line 8: | Line 8: | ||
CD56+, CK19 -ve, p63 -ve goes against PTC https://www.ncbi.nlm.nih.gov/pubmed/18254952 | CD56+, CK19 -ve, p63 -ve goes against PTC https://www.ncbi.nlm.nih.gov/pubmed/18254952 | ||
==Variation of thyroid cancer in Canada== | |||
Variation by City: https://journalotohns.biomedcentral.com/articles/10.1186/s40463-015-0088-0/tables/1 | |||
Variation by Province: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5621959/ |
Latest revision as of 15:44, 3 February 2022
http://www.sciencedirect.com/science/article/pii/S1110036215000096
"Encapsulated follicular thyroid tumor with equivocal nuclear changes, so-called well-differentiated tumor of uncertain malignant potential"
(1) Kakudo, K., Bai, Y., Liu, Z., Ozaki, T. Encapsulated papillary thyroid carcinoma, follicular variant: A misnomer. Pathology International 2012; 62: 155-160.
IHC
CD56+, CK19 -ve, p63 -ve goes against PTC https://www.ncbi.nlm.nih.gov/pubmed/18254952
Variation of thyroid cancer in Canada
Variation by City: https://journalotohns.biomedcentral.com/articles/10.1186/s40463-015-0088-0/tables/1
Variation by Province: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5621959/